Medpace Holdings Inc (MEDP)vsMerck & Company Inc (MRK)
MEDP
Medpace Holdings Inc
$418.66
+1.23%
HEALTHCARE · Cap: $11.81B
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 2327% more annual revenue ($65.01B vs $2.68B). MRK leads profitability with a 28.1% profit margin vs 17.2%. MEDP appears more attractively valued with a PEG of 2.54. MEDP earns a higher WallStSmart Score of 66/100 (B-).
MEDP
Strong Buy66
out of 100
Grade: B-
MRK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-5.3%
Fair Value
$402.51
Current Price
$418.66
$16.15 premium
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 77 in profit
Strong operational efficiency at 20.0%
Revenue surging 26.5% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Trading at 25.9x book value
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : MEDP
The strongest argument for MEDP centers on Return on Equity, Operating Margin, Revenue Growth. Profitability is solid with margins at 17.2% and operating margin at 20.0%. Revenue growth of 26.5% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bear Case : MEDP
The primary concerns for MEDP are P/E Ratio, PEG Ratio, Price/Book.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
MEDP profiles as a growth stock while MRK is a value play — different risk/reward profiles.
MEDP carries more volatility with a beta of 1.39 — expect wider price swings.
MEDP is growing revenue faster at 26.5% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MEDP scores higher overall (66/100 vs 59/100), backed by strong 17.2% margins and 26.5% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Medpace Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company is headquartered in Cincinnati, Ohio.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?